Aurobindo Pharma Limited

Aurobindo Pharma Limited

Aurobindo Pharma Limited and Elgi Rubber Company Limited have announced a special window for re-lodging transfer requests of physical shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The special window is open for a period of 1 year from February 5, 2026, to February 4, 2027. Shareholders are requested to update their KYC details and convert their physical shares into dematerialized form.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized/rematerialized during the quarter ended September 30, 2026, have been furnished to all the stock exchanges where the shares of the Company are listed.

Aurobindo Pharma Limited

Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg, with an estimated market size of US$ 67 million for the twelve months ending August 2026.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has completed the acquisition of the Contract Research Services business of A1 Biochem Group through its wholly-owned subsidiary Apitoria Pharma Private Limited.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the acquisition of A1 Biochem Labs LLC by A1 USA Inc, a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited. The acquisition aligns with the Company's strategic objective of expanding its presence in the life cycle of Active Pharmaceutical Ingredients (API) business.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the acquisition of 100% stake in A1 Biochem Labs (India) Private Limited by Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company. As part of the terms agreed under the definitive agreements, Dr. Rajendra Gadikota, former promoter of A1 Biochem group, has subscribed to 89,94,500 equity shares and 2,41,05,500 Compulsory Convertibles Debentures of A1 Labs, equaling to 20% stake (on a fully diluted basis).

Aurobindo Pharma Limited

Aurobindo Pharma's step-down subsidiary Acrotech Biopharma has launched ADQUEY, a non-steroidal topical treatment for atopic dermatitis, in the US market, marking the company's entry into the US dermatology market.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about an order passed by the Appellate Joint Commissioner (ST) confirming demand of Rs. 4,60,28,908/- (including interest and penalty) related to alleged excess claim of ITC amounting to Rs. 2,56,44,999/- for FY 2020-21. The company intends to file an appeal against the order.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about a scheduled investor/analyst meeting on September 24, 2026, in Hyderabad, where officials will discuss no unpublished price-sensitive information.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the completion of a US FDA inspection at its Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary, with one procedural observation.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has received final approval from the US FDA to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR Inhalation Aerosol 40 mcg and 80 mcg. This represents Aurobindo’s first metered-dose inhaler (MDI) product, marking a significant milestone in the Company’s expansion into complex respiratory therapies.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the acquisition of A1 Biochem USA Inc, a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited, which is a subsidiary of the Company. The acquisition is part of the earlier disclosed acquisition of A1 Biochem Group.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the completion of a US FDA inspection at its Unit-IV facility in Apitoria Pharma Private Limited, a wholly owned subsidiary, with zero observations.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about a scheduled investor/analyst meeting on September 22, 2026, with J. P. Morgan India.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about its participation in an investor / analyst meeting on September 21, 2026, with Bank of America 2026 Asia One-on-One and Hongkong 2026 5:00 PM (HKT) Pacific Conference Group Meetings.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about its participation in an investor/analyst meeting on September 17, 2026, in Hyderabad.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about a scheduled investor/analyst meeting on September 18, 2026, where company officials will participate in one-on-one and group meetings with Kotak Healthcare Forum.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has informed the Exchange about the schedule of an investor/analyst meeting to be held on September 17, 2026, in Hyderabad.

Aurobindo Pharma Limited

Aurobindo Pharma Limited has submitted a copy of a newspaper publication regarding the transfer of equity shares to the Investor Education and Protection Fund (IEPF) and the convening of the 62nd Annual General Meeting (AGM) through Video Conferencing (VC)/Other Audio Visual Means (OAVM) facility.